
    
      A Multi-Center, Double-Masked, Randomized, Phase 2 Evaluation of the Effectiveness of PR013
      Topical Ophthalmic Drops (0.045% and 0.06%) Compared to Vehicle of PR013 Topical Ophthalmic
      Drops for the Treatment of Allergic Conjunctivitis Using a Modified Conjunctival Allergen
      Challenge Model (Ora-CACÂ®)
    
  